Data from the trial will form part of the Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in order to proceed with phase two trials in children with these neurodevelopmental disorders. The second stage of the trial is expected to be completed in the December 2020 quarter. Neuren is up a slight 1.74 per cent and shares are trading for $1.75 each at 10:54 am AEST.